Omega Funds
VC Fund
Boston, United States
Omega Funds is a venture capital firm that seeks to invest in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and SaaS sectors.
- Total investments:
- 170
- Last investment:
- Lead investor:
- 28%
- Fund size:
- $470M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Omega Funds invests in
Stages Omega Funds invests in
Countries Omega Funds invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 13 contacts → | |||
Round size
- Series A
- $16M–$200M
- Series B
- $38M–$165M
- Series C
- $14M–$208M
Investment Focus
Industry
- Biotechnology 79 (46%)
- Health Care 46 (27%)
- Therapeutics 34 (20%)
- Pharmaceutical 33 (19%)
- Medical 32 (19%)
Stage
- Series A 39 (23%)
- Series B 36 (21%)
- Series C 17 (10%)
- Funding Round 15 (9%)
- Post-IPO Equity 9 (5%)
Country
- United States 73 (43%)
- Switzerland 8 (5%)
- United Kingdom 4 (2%)
- Germany 3 (2%)
- Canada 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michael Powell
Executive Partner
|
Executive Partner | Total investments: 12 | Find email | |
Michael Powell
Executive Partner
|
Executive Partner | Total investments: 6 | Find email | |
Otello Stampacchia
Founder
|
Founder | Total investments: 25 | Find email | |
Vincent Ossipow
Partner
|
Partner | Total investments: 5 | Find email | |
Alexia Pearsall
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
| See all 13 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Vaderis Therapeutics is a biotechnology company in the clinical stages that specializes in the treatment of uncommon and orphan diseases. | $152M / Series B / Aug 11, 2026 | ||
| Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field. | $165M / Series B / May 04, 2026 | ||
| It is a leading biotech company focused on immunology-related therapeutic areas. | $30M / Post-IPO Equity / Apr 13, 2026 | ||
| Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $52M / Series A / Feb 04, 2026 | ||
| Caldera was founded in 2025 to advance innovative biologics in IBD, assembling a senior leadership team with deep experience in the discovery and development of IBD therapeutics and a proven track record of building biotechnology companies through to successful exits.Caldera Therapeutics is a biotech company engaged in the development ofbispecific antibody CLD-423 for inflammatory bowel disease (IBD). | $37.5M / Series A / Jan 14, 2026 | ||
| Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M / Series A / Jan 08, 2026 | ||
| Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment. The company offers a drug-free approach to controlling severe, chronic airway diseases through its Spiro Neuromodulation System. | $67M / Series A / Jan 07, 2026 | ||
| Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M / Series B / Dec 01, 2025 | ||
| Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $115M / Series D / Nov 17, 2025 | ||
| NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M / Series B / Sep 08, 2025 | ||
| See all 170 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Omega Funds invest in?
Omega Funds invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 170 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Omega Funds's check size?
Omega Funds typically joins rounds of $16M–$200M at Series A, $38M–$165M at Series B and $14M–$208M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Omega Funds participates in.
How do I contact Omega Funds?
Public channels for Omega Funds include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Omega Funds?
The team at Omega Funds includes Michael Powell (Executive Partner), Michael Powell (Executive Partner) and Otello Stampacchia (Founder), among 13 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
